Every material Form 8-K Lineage Cell Therapeutics, Inc. has filed with the SEC since May 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Lineage Cell Therapeutics reported second quarter 2026 results, with net income attributable to Lineage of $1.5 million, or $0.01 per basic share, compared with a net loss of $30.5 million a year earlier. The profit was driven mainly by a $9.4 million non-cash gain from remeasuring warrant liabilities, while revenue fell to $1.1 million and the operating loss was $8.9 million, and diluted loss per share was $(0.03).
Total revenues were $1.1 million, down from $2.8 million a year earlier, mainly due to lower Roche collaboration revenue.
Loss from operations narrowed to $8.9 million from $19.8 million, which included a $14.8 million impairment in the prior-year quarter.
Other income of $10.5 million, mainly a $9.4 million warrant liability gain, produced net income attributable to Lineage of $1.5 million.
Cash, cash equivalents and marketable securities were $50.8 million as of June 30, 2026, which the company expects to support planned operations into Q3 2028.
At its June 10, 2026 annual meeting, shareholders elected seven directors, ratified Baker Tilly US, LLP as auditor for 2026, and approved the executive pay package on an advisory basis. Separately, on June 9, 2026, the company withdrew its application for a California Institute for Regenerative Medicine (CIRM) grant to support OPC1 development in spinal cord injury after receiving CIRM comments. The company states the withdrawal does not affect the ongoing DOSED study.
All seven board nominees were elected to serve until the 2027 annual meeting; Michael H. Mulroy received 90,383,337 votes for and 1,201,448 withheld.
Baker Tilly US, LLP was ratified for fiscal 2026 with 163,825,928 votes for, 659,670 against and 1,017,041 abstentions.
The advisory say-on-pay vote passed with 88,328,168 votes for, 2,600,932 against and 655,685 abstentions.
On June 9, 2026, the company withdrew its CIRM Clinical Trial (CLIN2) grant application, which it had filed in January 2026.
Lineage Cell Therapeutics reported first quarter 2026 results, with total revenues of $1.7 million, up from $1.5 million a year earlier. The net loss attributable to Lineage widened to $4.8 million, or $0.02 per share basic and $0.03 diluted, from $4.1 million, or $0.02 per share, in the prior-year quarter. The company said its $53.4 million in cash, cash equivalents and marketable securities is expected to support planned operations into Q2 2028.
Total revenues were $1.7 million for the quarter ended March 31, 2026, up $0.2 million, driven mainly by collaboration revenue under the new research collaboration agreement with William Demant Invest A/S (WDI).
Loss from operations was $7.6 million, compared with $6.5 million a year earlier, as total operating expenses rose to $9.3 million from $8.0 million.
Other income of $2.8 million, including a $2.3 million change in fair value of warrant liability, partly offset the operating loss.
Cash, cash equivalents and marketable securities totaled $53.4 million as of March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lineage Cell Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →